35th Anniversary Special: Breakthroughs and Emerging Technologies in Manufacturing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

35th Anniversary Special: Breakthroughs and Emerging Technologies in Manufacturing
Industry experts share their insight on solid-dosage and sterile manufacturing.


Pharmaceutical Technology
Volume 36, Issue 7, pp. 40-44, 58

PharmTech: Do you see solid-dosage manufacturing moving towards continuous processes?

Kettler (Natoli): In the academic and private sectors, work is being done to understand, from first principles, the tablet manufacturing process and the methods needed to monitor and control the unit processes involved. Some companies have proven that real-time release can be a reality. The companies that comprehend the need to develop continuous, controllable processes for pharmaceutical manufacturing by using QbD and advanced control techniques will harvest the rewards that come from running capable processes that can be operated by far fewer personnel and turned around faster than in the past. Costly deviations and lost batches will become events of yesteryear, and the level of regulatory oversight for these companies will fall to a level that will allow the inspectorate to spend its time overseeing the companies that continue to follow paths of greater risk.

Moreton (FinnBrit): I do think true continuous manufacturing—in which starting materials with predefined specifications are fed continuously and product is continually produced and removed from the process—is possible and can be achieved. Issues to be resolved include traceability in the event of a recall, contamination or adulteration of starting components, procedures for start-up and shut-down, and ways to deal with the inherent variability of the starting components. An interesting point is that many of the excipients used in the manufacture of pharmaceutical tablets and capsules are manufactured by true continuous manufacturing where the equipment is operated continuously 24 hours per day and seven days a week. These issues have been resolved for these materials, so why shouldn't they be resolvable for pharmaceutical tablets and capsules?

Oksanen (Pfizer): Large-volume products can benefit significantly from the efficiency and throughput improvements delivered by continuous processes. However, at the current time, we are seeing a trend towards smaller volume products due, in part, to our focus on personalized medicines. One key to effective manufacture of small-volume products is the development of flexible modular manufacturing units that can be quickly assembled anywhere. These units will have some of the aspects of continuous processing (especially where it improves robustness), but will be more flexible for multiple small volume products.

PharmTech: What may be the most significant advances of the next 5–10 years?

Kettler (Natoli): As the QbD mantra rises in volume, the use of PAT will increase in order to acquire more molecular and process information earlier in the development process. PAT generates large volumes of data and can be implemented on most drug-product unit operations. The institutions and individuals capable of managing this mountain of information and turning it into knowledge will gain a competitive advantage by learning to bring molecules to the clinic faster and being prepared to manufacture the final drug product at a lower cost. In five years, this will be a common practice for perhaps 10% of the pharmaceutical industry. In 10 years, there will be new measurement techniques that will come to bear on every one of the solid-dosage unit operations. These measurements will provide new insight into powder formulation, powder handling, and powder compaction processes. This new knowledge will offer the committed manufacturer the opportunity to design more processes based on first principles and the confidence that they can reach the end in mind with a minimum of experimental work to validate their design.

Oksanen (Pfizer): In the next five years, current research in API particle engineering will result in better control of API properties, enabling the use of simpler direct-compression processes for downstream drug-product processing. Within the next 10 years, the focus will be on technologies that improve efficiency in R&D and production. The development of flexible, modular manufacturing platforms for solid-dosage manufacturing will reduce the experimentation needed for technology transfer, getting drugs to market faster.

Knoch (Pfizer): The trend towards local manufacturing on a market-by-market basis is likely to drive demand for highly standardized, modular manufacturing units at medium-size scale and the flexibility to ensure manufacture of high quality product at any site with only limited operator input. Advanced process control will also play a bigger role. We will no longer just measure online intermediate and product attributes but will use feedback loops to optimize process parameters and product quality online. Ten years from now, the proportion of solid dosage forms will have decreased, and parenteral dosage forms of biotech products will play a bigger role.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here